{"name":"Dare Bioscience","slug":"dare","ticker":"DARE","exchange":"NASDAQ","domain":"darebioscience.com","description":"Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat","hq":"San Diego, CA","founded":0,"employees":"21","ceo":"Sabrina Martucci Johnson","sector":"Women's Health / Specialty Pharma","stockPrice":2.94,"stockChange":0.1,"stockChangePercent":3.52,"marketCap":"$43M","metrics":{"revenue":2807885,"revenueGrowth":-71.9,"grossMargin":71.3,"rdSpend":5523352,"netIncome":-13399274,"cash":24711356,"dividendYield":0,"peRatio":5,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Sildenafil Cream patent cliff ($0.00 at risk)","drug":"Sildenafil Cream","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Dare Bioscience Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Dare Bioscience reported its financial results for the fourth quarter and full year 2023, with a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Dare Bioscience Announces Collaboration with Pfizer to Develop Sildenafil Cream","summary":"Dare Bioscience announced a collaboration with Pfizer to develop Sildenafil Cream for the treatment of female sexual arousal disorder.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNbDNQd0xJRE9DdXluWjl0eGFrTHRaeFRrNWswd2FpQ0ZQb1piVDlFZ25zZnRHZTFId295VDdjT2VKSVgzQTAzR290TWxLclZfNFdzeEdXODR2bklPMlhEYUpzZkw0LW1ETVB4TXJPZkEwQVZVSEZkS2txVkx1Tm16bXBCLVVjbVY3OTJzYUtNUEJZSS1XUE8zOGFMVGVpelBwcno5X2MwbjVUX1Qz?oc=5","date":"2026-03-26","type":"pipeline","source":"Stock Titan","summary":"Daré Bioscience (NASDAQ: DARE) details 2025 loss, funding boost and upcoming product launches - Stock Titan","headline":"Daré Bioscience (NASDAQ: DARE) details 2025 loss, funding boost and upcoming product launches","sentiment":"neutral"},{"date":"2026-03-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPd1k3MlRoZzRTd2hGdUZzekoyTXVDNWtTMFVudFdibk01SnkwVjlsOURSblByZXdkOGZQblJlU0VKZVlac0w1TEktTVZHajRuY2hVWERtcTJzRHlsV1AxcG9hSTVxR1B6eHliTlhiZFNWcUxOVU9YUXZIQllMWkJMcVZkaW5LRUZmTkxFSTFlV0RGaGJWZVU4MzlVT0FtNE5jX205bU13?oc=5","date":"2026-03-23","type":"pipeline","source":"Stock Titan","summary":"A Viagra ingredient is now in a topical cream developed for women - Stock Titan","headline":"A Viagra ingredient is now in a topical cream developed for women","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQNXg5UUFnRlhkMDNNdFE1MWtwcEU2eXZWYTRZdkNnNGxLb1ctVk12RXBNVDM2OU5PSnl2cVotQlE1VFNpSFp5eFZYaEJ6LTBkRkdadnFFdmJIdFBWRmJ3NEpBWm90VV9RWjM0R0lsTHNCX1lKQnkzbEpsck9sc2pVVE5mTGRBdjlDNTEtbTZrdU9SQmVMbnl6UWxsQmc4dHdpTThhQVNOSEQ2SFNiYm5GWGxHYV9RM3gyMVBRSlZXa0JxU3lh?oc=5","date":"2026-02-16","type":"pipeline","source":"Femtech Insider","summary":"Daré Bioscience Launches Telehealth Access for DARE to PLAY, Its Topical Sildenafil Cream for Women - Femtech Insider","headline":"Daré Bioscience Launches Telehealth Access for DARE to PLAY, Its Topical Sildenafil Cream for Women","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxOemJ3Zndmc0dHUlJDNExpTXBmZDNiVHdwem9KUXY1WU5CQ29iNGwzVnREd2JmOTloZEs4QU03R196MFp6SU1CYlR1YXZCRHA5OFBxeDZ2MVFxdk14LURtRWpMREtCWHNNYUZzRk5oYmVyY3Nlekp6TDNiNHFJNUpUOEdUc3M0aW9WZ1ItMnBKcHpiNVB1NDZBNjhlOEk5Vm5mVFJTb05GWmlya1ozZGNydGVfUHg5bE1ySGw5dF9oNW1PLWhVQXlodUc2a1RXMGdMVDZieHVuaHFuRXFtd0piRF9aU2J2TFRZb1ZVNHBRQWZmOUxSR1pSSGY2aWxrdTZ5czliemMzaTFEVEpFTFdjeUdjOXJ6UQ?oc=5","date":"2026-02-11","type":"pipeline","source":"GlobeNewswire","summary":"Telehealth Now Available for DARE to PLAY™ Sildenafil - GlobeNewswire","headline":"Telehealth Now Available for DARE to PLAY™ Sildenafil","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-04","type":"pipeline","source":"simplywall.st","summary":"Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - simplywall.st","headline":"Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNa1dSSGxNYXZNaHNNNHhPNjVqSE0yeHZnWEJET0ZNNVBMMF9PTEhKZ1J6YlF1dnNhN184dDhYd3BMOGVEcktudVBHUFRTSC1CbVM0ZEpxOFRXOTh6dEgwRzFHMmJMSHZGSzZ1TFAtMEhyczhnVkVLRnZCNkJ4NFBUbGJabVQtZXFNSjhWUXd2VnlSdVFZdmVrN3M2Rmk5eHBiZ2dSU3dRVkU?oc=5","date":"2026-02-04","type":"pipeline","source":"Sahm","summary":"Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - Sahm","headline":"Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic?","sentiment":"neutral"},{"date":"2026-01-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPXzRsSjY5bE85ZF81UDczU2xmOWtYQ185YzUzb2F6QmZIc0hjS1dOZnhvRUhIVXVnODNab19wbENxQUR2UXR4YWxtb3R3WjlXOWZnZUZRWUlQS3VUeTBlbnY3ZUVGTGdHN1FJQmtaT3dPV09rQnM2YWwxQUR4UnVaN2Y4ZWNIX2o4cTA2YnhLeF9HMlpTN2tGWnl3VWdCcUFPQ2JySHVsTVA0dlZP?oc=5","date":"2025-12-11","type":"regulatory","source":"Femtech Insider","summary":"Daré Bioscience Opens Pre-Orders for Topical Sildenafil Cream for Female Arousal - Femtech Insider","headline":"Daré Bioscience Opens Pre-Orders for Topical Sildenafil Cream for Female Arousal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNWVoyNFBhQ3BuMnFjUm9sNXdPS3JXdTNYSHh3ZlNubXlObHBOX21aTTYzWHQ2SnZxUGlFSHJJd29wZlB2M3BhWXNqWjlkOXJvZWdNN19FaEI4b0w3VXVUSzVSZFcwblVMM2tNLV9EUVRJeFRaVlE2dWdtSG56VGpGVlNmYUI?oc=5","date":"2025-12-10","type":"pipeline","source":"Oprah Daily","summary":"Men Got Viagra in the ’90s—Could This First of Its Kind Topical Cream Quietly Rewrite Women’s Sexual Health Too? - Oprah Daily","headline":"Men Got Viagra in the ’90s—Could This First of Its Kind Topical Cream Quietly Rewrite Women’s Sexual Health Too?","sentiment":"neutral"}],"patents":[{"drugName":"Sildenafil Cream","drugSlug":"sildenafil","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Valeant Pharmaceuticals","Endo International","Allergan"],"therapeuticFocus":["Women's Health","Reproductive Medicine"],"financials":{"source":"sec_edgar+yahoo","revenue":2807885,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":2807885,"period":"2023-12-31"},{"value":10000000,"period":"2022-12-31"},{"value":10000000,"period":"2022-12-31"},{"value":0,"period":"2021-12-31"},{"value":766000,"period":"2016-12-31"}],"grossProfit":734394,"grossProfitHistory":[{"period":"2025-12-31","value":734394}],"rdSpend":5523352,"rdSpendHistory":[{"period":"2025-12-31","value":5523352},{"period":"2024-12-31","value":14305208},{"period":"2023-12-31","value":21538074},{"period":"2022-12-31","value":30042217}],"sgaSpend":8763376,"operatingIncome":-13552334,"operatingIncomeHistory":[{"period":"2025-12-31","value":-13552334},{"period":"2024-12-31","value":-23451485},{"period":"2023-12-31","value":-30939880},{"period":"2022-12-31","value":-31385488}],"netIncome":-13399274,"netIncomeHistory":[{"period":"2025-12-31","value":-13399274},{"period":"2024-12-31","value":-4053599},{"period":"2023-12-31","value":-30161391},{"period":"2022-12-31","value":-30947738}],"eps":-1.2,"epsHistory":[{"period":"2025-12-31","value":-1.2},{"period":"2024-12-31","value":-0.48},{"period":"2023-12-31","value":-4.15},{"period":"2022-12-31","value":-4.44}],"cash":24711356,"cashHistory":[{"period":"2025-12-31","value":24711356},{"period":"2024-12-31","value":15698174},{"period":"2023-12-31","value":10476056},{"period":"2022-12-31","value":34669605}],"totalAssets":32474563,"totalLiabilities":29631929,"totalDebt":2656019,"equity":2842634,"operatingCashflow":-9885870,"operatingCashflowHistory":[{"period":"2025-12-31","value":-9885870},{"period":"2024-12-31","value":5473555},{"period":"2023-12-31","value":-38856654},{"period":"2022-12-31","value":-18088429}],"capex":-385278,"capexHistory":[{"period":"2025-12-31","value":-385278},{"period":"2024-12-31","value":-573046},{"period":"2023-12-31","value":-629430},{"period":"2022-12-31","value":-63069}],"freeCashflow":-10271148,"dividendsPaid":null,"buybacks":null,"employees":21,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":1577104,"ebit":-1471268,"ebitda":-936873,"period":"2025-12-31","revenue":1023676,"epsBasic":null,"netIncome":-1441718,"rdExpense":622041,"epsDiluted":null,"grossProfit":727877,"operatingIncome":-1471268},{"sga":2499242,"ebit":-3672148,"ebitda":-3190242,"period":"2025-09-30","revenue":2262,"epsBasic":-0.28,"netIncome":-3562766,"rdExpense":1175168,"epsDiluted":-0.28,"grossProfit":2262,"operatingIncome":-3672148},{"sga":2377866,"ebit":-3827800,"ebitda":-3367725,"period":"2025-06-30","revenue":-21172,"epsBasic":-0.45,"netIncome":-4016483,"rdExpense":1428762,"epsDiluted":-0.45,"grossProfit":-21172,"operatingIncome":-3827800},{"sga":2309164,"ebit":-4581118,"ebitda":-4423008,"period":"2025-03-31","revenue":25427,"epsBasic":-0.5,"netIncome":-4378307,"rdExpense":2297381,"epsDiluted":-0.5,"grossProfit":25427,"operatingIncome":-4581118},{"sga":1921082,"ebit":-5388197,"ebitda":-5381829,"period":"2024-12-31","revenue":-63647,"epsBasic":null,"netIncome":-5506398,"rdExpense":3311142,"epsDiluted":null,"grossProfit":null,"operatingIncome":-5388197},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.55,"netIncome":null,"rdExpense":null,"epsDiluted":-0.55,"grossProfit":41691,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":2.94,"previousClose":2.84,"fiftyTwoWeekHigh":9.19,"fiftyTwoWeekLow":1.27,"fiftyTwoWeekRange":"1.27 - 9.19","fiftyDayAverage":1.99,"twoHundredDayAverage":1.99,"beta":1.09,"enterpriseValue":19293648,"forwardPE":5,"priceToBook":15.03,"priceToSales":41.62,"enterpriseToRevenue":18.73,"enterpriseToEbitda":-1.62,"pegRatio":0,"ebitda":-11917848,"ebitdaMargin":0,"freeCashflow":-4802669,"operatingCashflow":-9885870,"totalDebt":2656019,"debtToEquity":93.4,"currentRatio":1.14,"returnOnAssets":-31,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":3,"targetMeanPrice":9.67,"targetHighPrice":12,"targetLowPrice":8,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":8.3,"institutionHeldPercent":8.6,"sharesOutstanding":14559502,"floatShares":13311461,"sharesShort":358082,"shortRatio":0.43,"shortPercentOfFloat":2.5,"epsTrailing":-1.2,"epsForward":0.58,"revenuePerShare":0.09,"bookValue":0.2,"officers":[{"age":58,"name":"Ms. Sabrina Martucci Johnson","title":"CEO, President, Principal Financial Officer, Secretary & Director"},{"age":49,"name":"Ms. MarDee J. Haring-Layton","title":"Chief Accounting Officer"},{"age":70,"name":"Mr. Mark  Walters","title":"Vice President of Operations"},{"age":null,"name":"Dr. David  Friend Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Jennifer  Kiang","title":"Vice President of Corporate Affairs & Development"}],"industry":"Biotechnology","irWebsite":"","website":"https://darebioscience.com","phone":"858 926 7655"}}